HighField Biopharmaceuticals
PrivateLast Round
VC Round
Aug 8, 2024
Total Funding Raised
$15.7M
Company Overview
HighField Biopharmaceuticals operates in Healthcare & Life Sciences and is based in Hangzhou. Its latest recorded funding round was a VC Round in August 2024.
HighField Biopharmaceuticals is a clinical-stage biotechnology company that develops novel lipid-based therapeutics, including immunoliposomes and lipid nanoparticles, for the treatment of cancer, diabetes, and other complex diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
HighField Biopharmaceuticals Comparables
Compare HighField Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Acuitas Therapeutics | 75% | |
| NanoVation Therapeutics | 75% | |
| Genevant Sciences | 70% |
For institutional investors. Book with your work email.
HighField Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Aug 8, 2024 | ||||
| Series B | Dec 22, 2021 | ||||
| Series A | Sep 10, 2019 | ||||
| Angel | Dec 15, 2017 |
For institutional investors. Book with your work email.
HighField Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 杭州金投产业基金管理有限公司 | Series B |
| Hiway Capital | Series B, Series A |
| Hangzhou Finance and Investment Group | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 8, 2024
Completed a VC Round fundraise.
- Sep 10, 2019
Raised Series A with Hiway Capital and Hangzhou Tigermed.
For institutional investors. Book with your work email.
HighField Biopharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about HighField Biopharmaceuticals's valuation, stock price, and market status.
Is HighField Biopharmaceuticals a public or private company?
HighField Biopharmaceuticals is a private company.
What is the current stock price of HighField Biopharmaceuticals?
HighField Biopharmaceuticals is a private company, so its shares have no public market price. Caplight tracks HighField Biopharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is HighField Biopharmaceuticals worth (valuation)?
Valuation information for HighField Biopharmaceuticals is not publicly available.
Can I buy HighField Biopharmaceuticals stock?
HighField Biopharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was HighField Biopharmaceuticals's last funding round?
HighField Biopharmaceuticals's most recent funding round was VC Round on August 8, 2024.
Who are the main investors in HighField Biopharmaceuticals?
Key investors in HighField Biopharmaceuticals include 杭州金投产业基金管理有限公司, Hiway Capital, Hangzhou Finance and Investment Group.
Will HighField Biopharmaceuticals IPO soon?
No public IPO plans have been announced for HighField Biopharmaceuticals.
How can I track HighField Biopharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in HighField Biopharmaceuticals's shares on secondary markets.